Current Approach to the Diagnosis and Treatment of Heterozygote and Homozygous FH Children and Adolescents.

Current Atherosclerosis Reports
Hofit CohenThe Mighty Medic Satellite Research Group for Pediatric Dyslipidemia

Abstract

To elucidate the current approach of care in pediatric patients with familial hypercholesterolemia (FH). We sought an answer to the question whether the advances and major changes in lipid management are relevant and apply to children and adolescents. Latest research findings clearly demonstrate that lowering cholesterol levels at a young age prevents vascular atherosclerotic changes and decreases cardiovascular events in adulthood and emphasizes the importance of early detection and intervention in the pediatric FH patients group. FH is a common genetic disease caused by mutations in genes associated with the metabolism of low-density lipoproteins (LDL). The hallmark of FH is elevated LDL cholesterol (LDL-C) levels from birth and premature atherosclerotic cardiovascular disease (ASCVD). Often FH is either undiagnosed or diagnosed with a considerable delay, leading to vascular atherosclerotic changes and cardiovascular disease. Prompt identification of FH subjects is essential, to initiate early preventive measures. Safe and efficient pharmacological agents are approved for use in children and adolescents. Statins are the first line of therapy, in combination of ezetimibe. Unfortunately, these drugs do not warrant the achieveme...Continue Reading

References

Oct 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·T L InnerarityS M Grundy
Oct 23, 1997·Artificial Organs·C StefanuttiB Mazzarella
Jul 7, 2001·Acta Paediatrica·C StefanuttiS Bertolini
Oct 31, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Yoshio IwashimaYuhei Kawano
Dec 31, 2002·Journal of the American College of Cardiology·Saskia de JonghJohn J P Kastelein
May 6, 2003·Nature Genetics·Marianne AbifadelCatherine Boileau
Jun 17, 2004·Seminars in Vascular Medicine·Joep C DefescheJohn J P Kastelein
Jul 22, 2004·JAMA : the Journal of the American Medical Association·Albert WiegmanJohn J P Kastelein
Aug 1, 2007·Circulation·Jessica RodenburgBarbara A Hutten
May 28, 2008·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Jean-Bernard PalcouxBernard Roussel
Oct 23, 2008·Journal of the American College of Cardiology·Anouk van der GraafJohn J P Kastelein
Nov 13, 2008·BMJ : British Medical Journal·Jorie VersmissenEric J G Sijbrands
Apr 22, 2009·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Mahmut CokerSule Can
Sep 22, 2009·Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie·B LefortR Hankard
May 27, 2011·Journal of Clinical Lipidology·Anne C GoldbergUNKNOWN National Lipid Association Expert Panel on Familial Hypercholesterolemia
Aug 16, 2012·The Journal of Clinical Endocrinology and Metabolism·Marianne BennBørge G Nordestgaard
Sep 10, 2014·JAMA : the Journal of the American Medical Association·D Meeike KustersBarbara A Hutten
Nov 21, 2014·Current Atherosclerosis Reports·Claudia Stefanutti, Gilbert R Thompson
May 27, 2015·European Heart Journal·Albert WiegmanUNKNOWN European Atherosclerosis Society Consensus Panel
Jun 4, 2015·The New England Journal of Medicine·Christopher P CannonUNKNOWN IMPROVE-IT Investigators
Jun 11, 2015·The Journal of Pediatrics·Marjet J A M BraamskampUNKNOWN PASCAL Study Group
Aug 25, 2015·Nefrología : publicación oficial de la Sociedad Española Nefrologia·Mohamad AlkhouliYousef Boobes
Oct 30, 2016·The Journal of Pediatrics·Michael M MendelsonSarah D de Ferranti
Oct 27, 2016·The New England Journal of Medicine·David S WaldNicholas J Wald
Nov 15, 2016·Atherosclerosis·Michael FranceUNKNOWN for HEART UK Medical Scientific and Research Committee
Jan 28, 2017·Atherosclerosis·Kurt WidhalmGerhard Kostner
Feb 17, 2017·Therapeutic Advances in Chronic Disease·Daniel Hammersley, Mark Signy
Jun 3, 2017·Journal of Clinical Lipidology·Claudia StefanuttiUNKNOWN MIGHTY MEDIC Multinational Society
Aug 26, 2017·Journal of the American College of Cardiology·Evan A SteinJohn J P Kastelein

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

© 2021 Meta ULC. All rights reserved